Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2003

Heimdal K, Maehle L, Apold J, Pedersen J C, Møller P

Abstract excerpt

We aimed to describe the penetrances of the four Norwegian founder mutations in BRCA1 (816delGT, 1135insA, 1675delA and 3347delAG) with regard to breast and ovarian cancers in families ascertained through cancer family clinics or a consecutive series of women with breast or ovarian cancer. We hav...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Distribution
Share to Founder Effect
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Incidence

Share to Norway

Share to Ovarian Neoplasms

Share to Penetrance

Share to Risk Assessment

Source

Identifiers

PMID: 14522380
DOI: 10.1016/s0959-8049(03)00548-3

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-14522380-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.PMID 14522380Read ↗

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.Semantic proximity Read ↗

Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.Semantic proximity Read ↗

Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.Semantic proximity Read ↗

Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.Semantic proximity Read ↗

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.Semantic proximity Read ↗

BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.Semantic proximity Read ↗

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Semantic proximity Read ↗

BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in NorwaySemantic proximity Read ↗

Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.Semantic proximity Read ↗

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.Semantic proximity Read ↗

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.Semantic proximity Read ↗

A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.